HIF hydroxylation and the mammalian oxygen-sensing pathway

Journal of Clinical Investigation

Volumn 111, Issue 6, 2003, Pages 779-783

  Safran, Michal ^a   Kaelin Jr , William G ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; HYPOXIA INDUCIBLE FACTOR 1; OXYGEN; PROLINE DERIVATIVE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DNA BINDING PROTEIN; HIF1A PROTEIN, HUMAN; HIF3A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR 2, ALPHA SUBUNIT; LIGASE; NUCLEAR PROTEIN; PROLINE; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ASPARAGINE HYDROXYLATION; HYDROXYLATION; HYPOXIA; OXYGEN CONSUMPTION; OXYGEN SENSING PATHWAY; PRIORITY JOURNAL; PROLYL HYDROXYLATION; PROTEIN HYDROXYLATION; PROTEIN METABOLISM; REVIEW; VON HIPPEL LINDAU DISEASE; ANIMAL; GENETICS; HUMAN; METABOLISM;

ANIMALS; ASPARAGINE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; DNA-BINDING PROTEINS; HIPPEL-LINDAU DISEASE; HUMANS; HYDROXYLATION; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIGASES; NUCLEAR PROTEINS; OXYGEN; PROLINE; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0037362890     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200318181     Document Type: Review

References (75)

1. Bunn, H.F., and Poyton, R.O. 1996. Oxygen sensing and molecular adaptation to hypoxia. Physiol. Rev. 76:839-885.
2. Crews, S.T., and Fan, C.M. 1999. Remembrance of things PAS: regulation of development by bHLH-PAS proteins. Curr. Opin. Genet. Dev. 9:580-587.
3. Hogenesch, J.B., et al. 2000. The basic helix-loop-helix-PAS protein MOP9 is a brain-specific heterodimeric partner of circadian and hypoxia factors. J. Neurosci. 20:RC83.
4. Semenza, G.L. 2000. HIF1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88:1474-1480.
5. S. Semenza, G.L., et al. 1996. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271:32529-32537.
6. Carrero, P., et al. 2000. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1α. Mol. Cell Biol. 20:402-415.
7. Ema, M., et al. 1999. Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 18:1905-1914.
8. Arany, Z., et al. 1996. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl. Acad. Sci. U S. A. 93:12969-12973.
9. 2 tension. Proc. Natl. Acad. Sci. U. S. A. 92:5510-5514.
10. Huang, L.E., Arany, Z., Livingston, D.M., and Bunn, H.F. 1996. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J. Biol. Chem. 271:32253-32259.
11. Kallio, P.J., Pongratz, I., Gradin, K., McGuire, J., and Poellinger, L. 1997. Activation of hypoxia-inducible factor 1α: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc. Natl. Acad. Sci. U. S. A. 94:5667-5672.
12. Yu, A.Y., et al. 1998. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am. J. Physiol. 275:L818-L826.
13. Wiener, C.M., Booth, G., and Semenza, G.L. 1996. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. 225:485-488.
14. Collins, E.T. 1894. Intra-ocular growth (two cases, brother and sister, with peculiar new growth, probably retinal, affecting both eyes). Trans. Ophthalmol. Soc. U. K. 14:141-149.
15. Seizinger, B.R., et al. 1988. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 332:268-269.
16. Latif, F., et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 260:1317-1320.
17. Stolle, C., et al. 1998. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 12:417-423.
18. Maher, E.R., and Kaelin, W.G., Jr. 1997. von Hippel-Lindau disease. Medicine. 76:381-391.
19. Shuin, T., et al. 1999. Germline and somatic mutations in von Hippel-Lindau disease gene and its significance in the development of kidney cancer. Contrib. Nephrol. 128:1-10.
20. Shuin, T., et al. 1994. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54:2852-2855.
21. Foster, K., et al. 1994. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet. 3:2169-2173.
22. Whaley, J.M., er al. 1994. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am. J. Hum. Genet. 55:1092-1102.
23. Clifford, S.C., Prowse, A.H., Affara, N.A., Buys, C.H., and Maher, E.R. 1998. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer. 22:200-209.
24. Kanno, H., et al. 1994. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res. 54:4845-4847.
25. Tse, J.Y., et al. 1997. Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am. J. Clin. Pathol. 107:459-466.
26. Gnarra, J.R., et al. 1994. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7:85-90.
27. Renbaum, P., et al. 1996. Isolation and characterization of the full-length 3′ untranstated region of the human von Hippel-Lindau tumor suppressor gene. Hum. Genet. 98:666-671.
28. Iliopoulos, O., Kibel, A., Gray, S., and Kaelin, W.G.,Jr. 1995. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1:822-826.
29. Iliopoulos, O., Ohh, M., and Kaelin, W.G., Jr. 1998. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. U. S. A. 95:11661-11666.
30. Schoenfield, A., Davidowitz, E.J., and Burk, R.D. 1998. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. U. S. A. 95:8817-8822.
31. Blankenship, C., Naglich, J.G., Whaley, J.M., Seizinger, B., and Kley, N. 1999. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene. 18:1529-1535.
32. Iliopoulos, O., Levy, A.P., Jiang, C., Kaelin, W.G., Jr., and Goldberg, M.A. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl. Acad. Sci. U. S. A. 93:10595-10599.
33. Gnarra, J.R., et al. 1996. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the produce of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. U. S. A. 93:10589-10594.
34. Siemeister, G., et al. 1996. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56:2299-2301.
35. Krieg, M., Marti, H.H., and Plate, K.H. 1998. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood. 92:3388-3393.
36. Pause, A., et al. 1997. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of che Cdc53 family of proteins. Proc. Natl. Acad. Sci. U. S. A. 94:2156-2161.
37. Pause, A., Peterson, B., Schaffar, G., Stearman, R., and Klausner, R.D. 1999. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc. Natl. Acad. Sci. U. S. A. 96:9533-9538.
38. Kibel, A., Iliopoulos, O., DeCaprio, J.A., and Kaelin, W.G., Jr. 1995. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 269:1444-1446.
39. Lonergan, K.M., et al. 1998. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cu12. Mol. Cell. Biol. 18:732-741.
40. Kamura, T., et al. 1999. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 284:657-661.
41. Kishida, T., Stackhouse, T.M., Chen, F., Lerman, M.I., and Zbar, B. 1995. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res. 55:4544-4548.
42. Stebbins, C.E., Kaelin, W.G., Jr., and Pavletich, N.P. 1999. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 284:455-461.
43. Iwai, K., et al. 1999. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. U. S. A. 96:12436-12441.
44. Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M., and Krek, W. 1999. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13:1322-1833.
45. Maxwell, P.H., et al. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:271-275.
46. Ohh, M., et al. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2:423-427.
47. Kamura, T., et al. 2000. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. U. S. A. 97:10430-10435.
48. Cockman, M.E., et al. 2000. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275:25733-25741.
49. Tanimoto, K., Makino, Y., Pereira, T., and Poellinger, L. 2000. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19:4298-4309.
50. Yu, F., White, S.B., Zhao, Q., and Lee, F.S. 2001. Dynamic, site-specific interaction of hypoxia-inducible factor-1α with the von Hippel-Lindau tumor suppressor protein. Cancer Res. 61:4136-4142.
51. 2-regulated prolyl hydroxylation. Science. 292:468-472.
52. 2 sensing. Science. 292:464-468.
53. Yu, F., White, S.B., Zhao, Q., and Lee, F.S. 2001. HIF1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. U. S. A. 98:9630-9635.
54. Bruick, R.K., and McKnight, S.L. 2001. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 294:1337-1343.
55. Epstein, A.C., et al. 2001. C elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:43-54.
56. Ivan, M., et al. 2002. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl. Acad. Sci. U S. A. 99:13459-13464.
57. Taylor, M.S. 2001. Characterization and comparative analysis of the EGLN gene family. Gene. 275:125-132.
58. Aravind, L., and Koonin, E.V. 2001. The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases. Genome Biol. 2:RESEARCH0007.1-0007.8.
59. Masson, N., Willam, C., Maxwell, P.H., Pugh, C.W., and Ratcliffe, P.J. 2001. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J. 20:5197-5206.
60. Min, J.H., et al. 2002. Structure of an HIF1α-pVHL complex: hydroxyproline recognition in signaling. Science. 296:1886-1889.
61. Hon, W.C., et al. 2002. Structural basis for the recognition of hydroxyproline in HIF1α by pVHL. Nature. 417:975-978.
62. Bruick, R.K., and McKnight, S.L. 2002. Transcription. Oxygen sensing gets a second wind. Science. 295:807-808.
63. Lando, D.P., Peet, D.J., Whelan, D.A., Gorman, J.J., and Whitelaw, M.L. 2002. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science. 295:858-861.
64. Mahon, P.C., Hirota, K., and Semenza, G.L. 2001. FIH-1: a novel protein that interacts with HIF1α and VHL to mediate repression of HIF1 transcriptional activity. Genes Dev. 15:2675-2686.
65. Lando, D., et al. 2002. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16:1466-1471.
66. Hewitson, K.S., et al. 2002. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 277:26351-26355.
67. Dames, S.A., Martinez-Yamout, M., De Guzman, R.N., Dyson, H.J., and Wright, P.E. 2002. Structural basis for HIF 1α/CBP recognition in the cellular hypoxic response. Proc. Natl. Acad. Sci. U. S. A. 99:5271-5276.
68. Freedman, S.J., et al. 2002. Structural basis for recruitment of CBP/ p300 by hypoxia-inducible factor-1α. Proc. Natl. Acad. Sci. U. S. A. 99:5367-5372.
69. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., and Kaelin, W.G., Jr. 2002. Inhibition of HIF is necessary for rumor suppression by the von Hippel-Lindau protein. Cancer Cell. 1:237-246.
70. Maranchie, J.K., et al. 2002. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 1:247-255.
71. Drevs, J., et al. 2000. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 60:4819-4824.
72. Yang, J., Haworth, S., Steinberg, S., Rosenberg, S., and Novotny, W. 2002. A randomized double-blind placebo-controlled trail of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. 21:15 (Abstr.).
73. Vincent, K.A., et al. 2000. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF1α/VP16 hybrid transcription factor. Circulation. 102:2255-2261.
74. Elson, D.A., et al. 2001. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev. 15:2520-2532.
75. Nwogu, J.I., et al. 2001. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation. 104:2216-2221.